Update on antibiotics for infection control in cystic fibrosis

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 967-980

  Kirkby, Stephen ^a   Novak, Kimberly ^a   McCoy, Karen ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Burkholderia cepacia complex; Cystic fibrosis; Pseudomonas aeruginosa; Staphylococcus aureus; Treatment

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CEFALEXIN; CEFDINIR; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MEROPENEM; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; BLOOD DYSCRASIA; BRONCHIECTASIS; BRONCHOSPASM; BURKHOLDERIA CEPACIA; CHRONIC DISEASE; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DYSPHONIA; DYSPNEA; ERADICATION THERAPY; GRAM NEGATIVE BACTERIUM; GRAY BABY SYNDROME; HOARSENESS; HUMAN; HYPERKALEMIA; INFECTION CONTROL; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LUNG DISEASE; MAINTENANCE THERAPY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYALGIA; MYCOBACTERIUM; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OVERALL SURVIVAL; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; PRURITUS; PSEUDOMONAS AERUGINOSA; RECURRENT DISEASE; RED MAN SYNDROME; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SEIZURE; SERUM SICKNESS; SORE THROAT; STAPHYLOCOCCUS AUREUS; SYNDROME; TASTE DISORDER; TENDON RUPTURE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TINNITUS; TOOTH DISCOLORATION; VESTIBULAR DISORDER; VOMITING;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 70350593962     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.82     Document Type: Review

References (129)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154(5), 1229-1256 (1996).
2. Davis PB. Cystic fibrosis since 1938. Am. J. Respir. Crit. Care Med. 1173(5), 475-482 (2006).
3. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168(8), 918-951 (2003). •• Comprehensive review of pathogenesis and treatment of cystic fibrosis (CF) pulmonary/ infectious disease.
4. Cystic Fibrosis Foundation Patient Registry. 2007 Annual Data Report. ©2009 Cystic Fibrosis Foundation, Bethesda, MD, USA (2007).
5. Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957-969 (2007). •• Evidence-based guidelines for the maintenance of pulmonary health, including chronic antibiotic use.
6. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Trust Antibiotic Working Group (3rd Edition). London, UK (2009). •• Evidence-based consensus statement on antibiotic use from the Cystic Fibrosis Trust.
7. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N. Engl. J. Med. 352(19), 1992-2001 (2005).
8. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407(6805), 762-764 (2000).
9. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Resp. Care 54(5), 628-640 (2009).
10. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell. Microbiol. 11(7), 1034-1043 (2009).
11. Wagner VE, Iglewski BH. P. aeruginosa biofilms in CF infection. Clin. Rev. Allergy Immunol. 35(3), 124-134 (2008).
12. Linnane BM, Hall GL, Nolan G et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am. J. Respir. Crit. Care Med. 178(12), 1238-1244 (2008).
13. Armstrong DS, Hook SM, Jamsen KM et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 40(6), 500-510 (2005).
14. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(8), 814-821 (2008). • Describes the detrimental role that persistent methicillin-resistant Staphylococcus aureus infection may play in CF.
15. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34(2), 91-100 (2002). • Describes the natural history of Pseudomonas aeruginosa infection in CF.
16. Rosenfeld M, Gibson RL, McNamara S et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32(5), 356-366 (2001). (Pubitemid 33015652)
17. LiPuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin. Respir. Crit. Care Med. 24(6), 681-692 (2003).
18. Rosenfeld M, Emerson J, Williams-Warren J et al. Defining a pulmonary exacerbation in cystic fibrosis. J. Paediatr. 139(3), 359-365 (2001).
19. Rabin HR, Butler SM, Wohl ME et al. Pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 37(5), 400-406 (2004).
20. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur. Respir. J. 10(4), 896-900 (1997).
21. Pond MN, Newport M, Joanes D, Conway SP. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur. Respir. J. 7(9), 1640-1644 (1994).
22. Proesmans M, Heyns L, Moons P, Havermans T, De Boeck K. Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir. Med. 103(2), 244-250 (2009).
23. Nazer D, Abdulhamid I, Thomas R, Pendleton S. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis. Pediatr. Pulmonol. 41(8), 744-749 (2006). (Pubitemid 44157357)
24. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr. Pulmonol. 24(1), 42-47 (1997).
25. Douglas TA, Brennan S, Gard S et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur. Respir. J. 33(2), 305-311 (2009).
26. Gondor M, Nixon PA, Mutich R, Rebovich P, Orenstein DM. Comparison of flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr. Pulmonol. 28(4), 255-260 (1999). (Pubitemid 29468459)
27. Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study. Pediatr. Pulmonol. 19(1), 16-22 (1995).
28. Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293(5), 581-588 (2005). • Describes the natural history of P. aeruginosa infection in CF.
29. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8(3), 249-255 (2007).
30. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366(9484), 463-471 (2005). (Pubitemid 41111694)
31. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 3, CD006961 (2008).
32. Remmington T, Jahnke N, Harkensee C. Oral antipseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD005405 (2007). (Pubitemid 351805585)
33. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J. Paediatr. 11(1), 28-33 (1987). (Pubitemid 17092642)
34. Bockenhauer D, Hug MJ, Kleta R. Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin. Pediatr. Nephrol. 24(5), 925-928 (2009).
35. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol. 39(1), 15-20 (2005). (Pubitemid 39628598)
36. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet. Med. 9(10), 695-704 (2007).
37. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121(1), 55-63 (2002).
38. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 7(6), 523-530 (2008).
39. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 1, CD004197 (2006).
40. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999). •• Historical paper establishing the basis for the maintenance of inhaled tobramycin use.
41. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20(3), 658-664 (2002).
42. Ryan G, Mukhopadhyay S, Singh M. Nebulised antipseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001021 (2003).
43. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N. Engl. J. Med. 357(22), 2310-2311 (2007).
44. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(9), 921-928 (2008).
45. Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin. Respir. Crit. Care Med. 24(6), 717-726 (2003).
46. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 42(4), 307-313 (2007). (Pubitemid 46608898)
47. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 350(4), 977-982 (2006). (Pubitemid 44584188)
48. Legssyer R, Huaux F, Lebacq J et al. Azithromycin reduces spontaneous and induced inflammation in dF508 cystic fibrosis mice. Respir. Res. 7, 134 (2006). (Pubitemid 44774213)
49. Oliynyk I, Varelogianni G, Schalling M, Asplund MS, Roomans GM, Johannesson M. Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells. Exp. Lung Res. 35(3), 210-221 (2009).
50. Hoffmann N, Lee B, Hentzer M et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth- phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 51(10), 3677-3687 (2007).
51. Halldorsson S, Gudjonsson T, Gottfredsson M, Singh PK, Gudmundsson GH, Baldursson O. Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am. J. Respir. Cell Mol. Biol. (2009) (Epub ahead of print).
52. Bergamini G, Cigana C, Sorio C et al. Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. Am. J. Respir. Cell Mol. Biol. 41(2), 199-206 (2009).
53. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290(13), 1749-1756 (2003). •• Historical paper establishing the basis for the maintenance oral azithromycin use.
54. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360(9338), 978-984 (2002). (Pubitemid 35284109)
55. Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur. Respir. J. 24(5), 834-838 (2004).
56. Goodrich JS, Sutton-Shields TN, Kerr A, Wedd JP, Miller MB, Gilligan PH. Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J. Clin. Microbiol. 47(4), 1231-1233 (2009).
57. Sawicki GS, Rasouliyan L, Pasta DJ et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 43(11), 1117-1123 (2008).
58. Sagel SD, Gibson RL, Emerson J et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Paediatr. 154(2), 183-188 (2009).
59. Elizur A, Orscheln RC, Ferkol TW et al. Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 131(6), 1718-1725 (2007).
60. Elizur A, Orscheln RC, Ferkol TW, Dunne WM Jr, Storch GA, Cannon CL. Transmission of Panton-Valentine leukocidin-positive Staphylococcus aureus between patients with cystic fibrosis. J. Paediatr. 151(1), 90-92 (2007). (Pubitemid 46935192)
61. Spicuzza L, Sciuto C, La Rosa M. Safety and efficacy of long-term treatment with linezolid in cystic fibrosis: case report. J. Chemother. 20(3), 399-401 (2008). (Pubitemid 351998911)
62. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33(3), 221-223 (2002).
63. Santos RP, Prestidge CB, Brown ME et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr. Pulmonol. 44(2), 148-154 (2009).
64. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 48(1), 281-284 (2004).
65. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Paediatr. 140(3), 299-305 (2002).
66. Hansen CR, Pressler T, Hoiby N, Johansen HK. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J. Cyst. Fibros. 8(1), 58-62 (2009).
67. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001912 (2003).
68. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr. Pulmonol. 36(3), 189-195 (2003). (Pubitemid 37055965)
69. Serisier DJ, Jones G, Carroll M. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J. Cyst. Fibros. 3(1), 61 (2004). (Pubitemid 38397026)
70. Ellaffi M, Vinsonneau C, Coste J et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 171(2), 158-164 (2005).
71. De Boeck K, Malfroot A, Van Schil L et al. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur. Respir. J. 23(6), 851-856 (2004).
72. Jones AM, Dodd ME, Govan JR et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59(11), 948-951 (2004).
73. Weidmann A, Webb AK, Dodd ME, Jones AM. Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. J. Cyst. Fibros. 7(5), 409-411 (2008).
74. Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 179(3), 257-258 (2009). • Describes findings that individual Burkholderia cepacia complex species may effect transplant outcome.
75. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(4), 363-371 (2008).
76. Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur. Respir. J. 6(2), 305-308 (2005).
77. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161(4 Pt 1), 1206-1212 (2000).
78. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59(11), 955-959 (2004).
79. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166(3), 356-361 (2002). (Pubitemid 34864426)
80. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6(1), 75-78 (2007). (Pubitemid 46029892)
81. Rønne Hansen C, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J. Cyst. Fibros. 5(4), 245-251 (2006). (Pubitemid 44824860)
82. Elborn JS. Identification and management of unusual pathogens in cystic fibrosis. J. R. Soc. Med. 101(Suppl. 1), S2-S5 (2008).
83. Davies JC, Rubin BK. Emerging and unusual Gram-negative infections in cystic fibrosis. Semin. Respir. Crit. Care Med. 28(3), 312-321 (2007).
84. Saiman L, Chen Y, Tabibi S et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39(11), 3942-3945 (2001).
85. Lipuma JJ. Update on the Burkholderia cepacia complex. Curr. Opin. Pulm. Med. 11(6), 528-533 (2005).
86. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109(3), 317-325 (2002). (Pubitemid 34141805)
87. Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177(9), 995-1001 (2008). • Describes the high prevalence of anaerobic species in CF respiratory samples.
88. Bittar F, Richet H, Dubus JC et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PloS One 3(8), e2908 (2008).
89. Levy I, Grisaru-Soen G, Lerner-Geva L et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerging Infect. Dis. 14(3), 378-384 (2008).
90. Olivier KN, Weber DJ, Wallace RJ Jr et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167(6), 828-834 (2003).
91. Olivier KN, Weber DJ, Lee JH et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167(6), 835-840 (2003).
92. Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J. Heart Lung Transplant. 25(8), 985-988 (2006).
93. Zaidi S, Elidemir O, Heinle JS et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl. Infect. Dis. 11(3), 243-248 (2009).
94. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 641-645 (2000).
95. Sanguinetti M, Ardito F, Fiscarelli E et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J. Clin. Microbiol. 39(2), 816-819 (2001). (Pubitemid 32150872)
96. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175(4), 367-416 (2007). • Comprehensive guidelines for the diagnosis and treatment of nontuberculous mycobacterial infections.
97. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ 3rd. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonaelike organisms. Antimicrob. Agents Chemother. 36(1), 180-184 (1992).
98. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am. Rev. Respir. Dis. 147(5), 1271-1278 (1993).
99. Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr. Pulmonol. 30(3), 267-268 (2000).
100. Touw DJ, Vinks AA, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin. Pharmacokinet. 35(6), 437-459 (1998).
101. Bates RD, Nahata MC, Jones JW et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 112(5), 1208-1213 (1997).
102. Master V, Roberts GW, Coulthard KP et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr. Pulmonol. 31(5), 367-376 (2001). (Pubitemid 32417255)
103. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob. Agents Chemother. 44(4), 809-813 (2000).
104. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 365(9459), 573-578 (2005). (Pubitemid 40247913)
105. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J. Cyst. Fibros. 6(5), 327-333 (2007). (Pubitemid 47324148)
106. Han EE, Beringer PM, Falck P et al. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 57(5), 1017-1019 (2006).
107. Hubert D, Le Roux E, Lavrut T et al. Continuous versus intermittent infusions of ceftazidime for exacerbation of cystic fibrosis. Antimicrob. Agents Chemother. 53(9), 3650-3656 (2009).
108. Rappaz I, Decosterd LA, Bille J, Pilet M, Belaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur. J. Paediatr. 159(12), 919-925 (2000). (Pubitemid 30951269)
109. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin. Ther. 26(4), 493-501 (2004).
110. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12), 563-570 (2007).
111. Tsifansky MD, Yeo Y, Evge OV, Bellas E, Benjamin J, Kohane DS. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 10(2), 254-260 (2008).
112. LiPuma JJ, Rathinavelu S, Foster BK et al. In vitro activities of a el nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob. Agents Chemother. 53(1), 249-255 (2009).
113. Pilcer G, Goole J, Van Gansbeke B et al. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur. J. Pharm. Biopharm. 68(2), 413-421 (2008).
114. Westerman EM, de Boer AH, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int. J. Pharm. 335(1-2), 41-45 (2007).
115. Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 305(1-2), 180-185 (2005). (Pubitemid 41568373)
116. Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol Med. Pulm. Drug Deliv. 21(3), 245-254 (2008).
117. Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J. Antimicrob. Chemother. 60(4), 760-769 (2007). (Pubitemid 47434253)
118. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin. Drug Deliv. 3(5), 693-702 (2006). (Pubitemid 44383495)
119. Boyle MP. Strategies for identifying modifier genes in cystic fibrosis. Proc. Am. Thorac. Soc. 4(1), 52-57 (2007).
120. Drumm ML, Konstan MW, Schluchter MD et al. Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med. 353(14), 1443-1453 (2005).
121. Dorfman R, Sandford A, Taylor C et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest. 118(3), 1040-1049 (2008).
122. Gu Y, Harley IT, Henderson LB et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 458(7241), 1039-1042 (2009).
123. Welch EM, Barton ER, Zhuo J et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447(7140), 87-91 (2007). (Pubitemid 46685839)
124. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372(9640), 719-727 (2008).
125. Van Goor F, Straley KS, Cao D et al. Rescue of dF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. 290(6), L1117-L1130 (2006).
126. Clunes MT, Boucher RC. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr. Opin. Pharmacol. 8(3), 292-299 (2008).
127. Deterding RR, Lavange LM, Engels JM et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med. 176(4), 362-369 (2007).
128. Grasemann H, Stehling F, Brunar H et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131(5), 1461-1466 (2007). (Pubitemid 46762353)
129. Cystic fibrosis Foundation Patient Registry. Annual Data Report (2007) www.cff.org/UploadedFiles/research/ClinicalResearch/2007-Patient-Registry- Report.pdf